News & Events
Newave Presents the Latest Results of LP-118 at the 63rd ASH Annual Meeting
December 13, 2021: 2:45 PM (EST), Newave Pharmaceutical presented the latest data of its own proprietary LP-118, the next generation of Bcl-2 inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.
14 Nov 2021 01:00:00
Newave/Lupeng Pharmaceutical Completed a $35 Million Pre-B Funding for Novel Drugs
San Francisco, CA, July 27, 2021- Lupeng Pharmaceutical, a privately-held biopharmaceutical company, and its fully owned US subsidiary (Newave Pharmaceutical Inc.), today announced the closing of a $35 million pre-B round of financing.
29 Jul 2021 01:00:00